List of bibliographic references
Number of relevant bibliographic references: 7.
| Ident. | Authors (with country if any) | Title |
|---|
| 000118 (2017) |
Tarik Asselah [France] ; Stefan Bourgeois [Belgique] ; Stephen Pianko [Australie] ; Stefan Zeuzem [Allemagne] ; Mark Sulkowski [États-Unis] ; Graham R. Foster [Royaume-Uni] ; Lingling Han [États-Unis] ; John Mcnally [États-Unis] ; Anu Osinusi [États-Unis] ; Diana M. Brainard [États-Unis] ; G Mani Subramanian [États-Unis] ; Edward J. Gane [Nouvelle-Zélande] ; Jordan J. Feld [Canada] ; Alessandra Mangia [Italie] | Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. |
| 000319 (2017) |
David Wyles [États-Unis] ; Heiner Wedemeyer [Allemagne] ; Ziv Ben-Ari [Israël] ; Edward J. Gane [Nouvelle-Zélande] ; Jesper Bach Hansen [Danemark] ; Ira M. Jacobson [États-Unis] ; Alex L. Laursen [Danemark] ; Annie Luetkemeyer [États-Unis] ; Ronald Nahass [États-Unis] ; Stephen Pianko [Australie] ; Stefan Zeuzem [Allemagne] ; Patricia Jumes [États-Unis] ; Hsueh-Cheng Huang [États-Unis] ; Joan Butterton [États-Unis] ; Michael Robertson [États-Unis] ; Janice Wahl [États-Unis] ; Eliav Barr [États-Unis] ; Hee-Koung Joeng [États-Unis] ; Elizabeth Martin [États-Unis] ; Lawrence Serfaty [France] | Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. |
| 000404 (2017) |
Ira M. Jacobson [États-Unis] ; Eric Lawitz [États-Unis] ; Edward J. Gane [Nouvelle-Zélande] ; Bernard E. Willems [Canada] ; Peter J. Ruane [États-Unis] ; Ronald G. Nahass [États-Unis] ; Sergio M. Borgia [Canada] ; Stephen D. Shafran [Canada] ; Kimberly A. Workowski [Géorgie (pays)] ; Brian Pearlman [Géorgie (pays)] ; Robert H. Hyland [États-Unis] ; Luisa M. Stamm [États-Unis] ; Evguenia Svarovskaia [États-Unis] ; Hadas Dvory-Sobol [États-Unis] ; Yanni Zhu [États-Unis] ; G Mani Subramanian [États-Unis] ; Diana M. Brainard [États-Unis] ; John G. Mchutchison [États-Unis] ; Norbert Br U [États-Unis] ; Thomas Berg [Allemagne] ; Kosh Agarwal [Royaume-Uni] ; Bal Raj Bhandari [États-Unis] ; Mitchell Davis [États-Unis] ; Jordan J. Feld [Canada] ; Gregory J. Dore [Australie] ; Catherine A M. Stedman [Nouvelle-Zélande] ; Alexander J. Thompson [Australie] ; Tarik Asselah [France] ; Stuart K. Roberts [Australie] ; Graham R. Foster [Royaume-Uni] | Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. |
| 000808 (2016) |
Michael Manns [Allemagne] ; Didier Samuel [France] ; Edward J. Gane [Nouvelle-Zélande] ; David Mutimer [Royaume-Uni] ; Geoff Mccaughan [Australie] ; Maria Buti [Espagne] ; Martín Prieto [Espagne] ; José Luis Calleja [Espagne] ; Markus Peck-Radosavljevic [Autriche] ; Beat Müllhaupt [Suisse] ; Kosh Agarwal [Royaume-Uni] ; Peter Angus [Australie] ; Eric M. Yoshida [Canada] ; Massimo Colombo [Italie] ; Mario Rizzetto [Italie] ; Hadas Dvory-Sobol [États-Unis] ; Jill Denning [États-Unis] ; Sarah Arterburn [États-Unis] ; Phillip S. Pang [États-Unis] ; Diana Brainard [États-Unis] ; John G. Mchutchison [États-Unis] ; Jean-François Dufour [Suisse] ; Hans Van Vlierberghe [Belgique] ; Bart Van Hoek [Pays-Bas] ; Xavier Forns [Espagne] | Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. |
| 000D36 (2015) |
Stefan Zeuzem [Allemagne] ; Vicente Soriano [Espagne] ; Tarik Asselah [France] ; Edward J. Gane [Nouvelle-Zélande] ; Jean-Pierre Bronowicki [France] ; Peter Angus [Australie] ; Ansgar W. Lohse [Allemagne] ; Felix Stickel [Suisse] ; Beat Müllhaupt [Suisse] ; Stuart Roberts [Australie] ; Marcus Schuchmann [Allemagne] ; Michael Manns [Allemagne] ; Marc Bourlière [France] ; Maria Buti [Espagne] ; Jerry O. Stern [États-Unis] ; John-Paul Gallivan [Allemagne] ; Florian Voss [Allemagne] ; John P. Sabo [États-Unis] ; Wulf Böcher [Allemagne] ; Federico J. Mensa [États-Unis] | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis |
| 000E58 (2015) |
Tarik Asselah [France] ; Stefan Zeuzem [Allemagne] ; Vicente Soriano [Espagne] ; Jean-Pierre Bronowicki [France] ; Ansgar W. Lohse [Allemagne] ; Beat Müllhaupt [Suisse] ; Marcus Schuchmann [Allemagne] ; Marc Bourlière [France] ; Maria Buti [Espagne] ; Stuart K. Roberts [Australie] ; Edward J. Gane [Nouvelle-Zélande] ; Jerry O. Stern [États-Unis] ; Florian Voss [Allemagne] ; Patrick Baum [Allemagne] ; John-Paul Gallivan [Allemagne] ; Wulf O. Böcher [Allemagne] ; Federico J. Mensa [États-Unis] | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection |
| 001E49 (2010) |
Savino Bruno [Italie] ; Mitchell L. Shiffman [États-Unis] ; Stuart K. Roberts [Australie] ; Edward J. Gane [Nouvelle-Zélande] ; Diethelm Messinger [Allemagne] ; Stephanos J. Hadziyannis [Grèce] ; Patrick Marcellin [France] | Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Female |
| 4 | Humans |
| 4 | Male |
| 4 | Middle Aged |
| 3 | Antiviral Agents (therapeutic use) |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 2 | Adult |
| 2 | Aged |
| 2 | Aged, 80 and over |
| 2 | Antiviral Agents (adverse effects) |
| 2 | Benzimidazoles (therapeutic use) |
| 2 | Drug Therapy, Combination |
| 2 | Genotype |
| 2 | Hepacivirus (drug effects) |
| 2 | Hepatitis C, Chronic (complications) |
| 2 | Liver Cirrhosis (drug therapy) |
| 2 | Ribavirin (therapeutic use) |
| 2 | Young Adult |
| 1 | Acrylates (adverse effects) |
| 1 | Acrylates (pharmacology) |
| 1 | Acrylates (therapeutic use) |
| 1 | Adolescent |
| 1 | Anemia (diagnosis) |
| 1 | Anemia (etiology) |
| 1 | Antineoplastic agent |
| 1 | Antiviral |
| 1 | Antiviral Agents (administration & dosage) |
| 1 | Antiviral Agents (pharmacology) |
| 1 | Benzimidazoles (adverse effects) |
| 1 | Benzimidazoles (pharmacology) |
| 1 | Carbamates (administration & dosage) |
| 1 | Carbamates (adverse effects) |
| 1 | Carbamates (therapeutic use) |
| 1 | Cirrhosis |
| 1 | Fibrosis |
| 1 | Fluorenes (therapeutic use) |
| 1 | Gastroenterology |
| 1 | Global Health |
| 1 | Hepacivirus (classification) |
| 1 | Hepacivirus (genetics) |
| 1 | Hepatitis C (complications) |
| 1 | Hepatitis C (drug therapy) |
| 1 | Hepatitis C (virology) |
| 1 | Hepatitis C, Chronic (mortality) |
| 1 | Heterocyclic Compounds, 4 or More Rings (administration & dosage) |
| 1 | Heterocyclic Compounds, 4 or More Rings (adverse effects) |
| 1 | Heterocyclic Compounds, 4 or More Rings (therapeutic use) |
| 1 | Human |
| 1 | Immunomodulator |
| 1 | Interferons (metabolism) |
| 1 | Liver Cirrhosis (complications) |
| 1 | Liver Cirrhosis (mortality) |
| 1 | Liver Cirrhosis (virology) |
| 1 | Macrocyclic Compounds (administration & dosage) |
| 1 | Macrocyclic Compounds (adverse effects) |
| 1 | Macrocyclic Compounds (therapeutic use) |
| 1 | Oligopeptides (adverse effects) |
| 1 | Oligopeptides (pharmacology) |
| 1 | Oligopeptides (therapeutic use) |
| 1 | Peginterferon alfa-2a |
| 1 | Polymorphism, Single Nucleotide (genetics) |
| 1 | Pyrophosphatases (genetics) |
| 1 | RNA, Viral |
| 1 | Real-Time Polymerase Chain Reaction |
| 1 | Ribavirin |
| 1 | Ribavirin (adverse effects) |
| 1 | Ribavirin (pharmacology) |
| 1 | Sofosbuvir (administration & dosage) |
| 1 | Sofosbuvir (adverse effects) |
| 1 | Sofosbuvir (therapeutic use) |
| 1 | Sulfonamides (administration & dosage) |
| 1 | Sulfonamides (adverse effects) |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Sustained Virologic Response |
| 1 | Thiazoles (adverse effects) |
| 1 | Thiazoles (pharmacology) |
| 1 | Thiazoles (therapeutic use) |
| 1 | Time Factors |
| 1 | Toxicity |
| 1 | Treatment Outcome |
| 1 | Uridine Monophosphate (analogs & derivatives) |
| 1 | Uridine Monophosphate (therapeutic use) |
| 1 | Viral Load |
| 1 | Viral hepatitis C |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Edward J. Gane"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Edward J. Gane" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Edward J. Gane
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
